Said BUY IT phase 3 data at hand.
The pps will be in direction relation to revenue and eps. with a premium for any non marketed phase 2-3 items. Throwing a number out there be it 17, 30, 50, or 100 is meaningless. Through out a revenue number to go with a price target, a percent market share achieved per indication and you will have my attention. Picking a number like 17 equates to about 400-500m in revenue, Opko will do more than that by a few billion.
U R in at a better price than I am, so I am glad about that. I hate when some one buys a stock I am in and it then drops, ouch, I always feel guilty. But I buy hold, 3 year windows, most know that, daily moves mean nothing. This one will take time, the ATM hurts it short term. Hope I am right on both, time will tell, 2016 both should be up 2-4 fold if 10% of the pipelines pan out.
So realistically how are shorts going to find 17m shares to cover, funds usually do not trade daily, only 12.5m in retail hands, funds net buyers last Q by 1.8m, 10 days to cover. This item is set up nicely to rocket on positive phase 3 news.
First to cover wins, period.
Cover, is the best, safest play, buy puts.
getting arry back near year high. Under 5.00 IS A BUY.
as evinced by onty move too.
9.00, short term, but longer term no higher target but bullish. From Piper:
Piper Jaffray says shares of Array BioPharma are attractive at current levels ahead of Phase III data readouts for binimetinib in melanoma, selumetinib in Kras-mutant lung, thyroid and uveal melanoma, and filanesib in multiple myeloma. Piper sees the biggest overhang on Array shares as being the financing requirement and it notes that binimetinib could be returned to the company from current partner Novartis (NVS). Nonetheless, it feels investors should take a "serious look" at Array and keeps an Overweight rating on the stock with a $9 price target.
Frost is doing a 2 billion dollar share buy back program for Opko using his cash, not Opko's. So far their is another 1.5B in available cash to buy shares, lol. Opko's hemophilia drug looks to have an advantage over Biogen's newly approved drug. Biogen's injections are every 4 days, two indications, Opko's every 7 days, 4 indications, so broader applicability and less frequent dosage, a 7 billion dollar market according to Biogen.
over 18% on the puma news. Guess market is figuring if the puma pan-her worked the arry/onty will too. The arry/onty is only phase 1, arry does also own a phase2 so those drugs are about 3 years away. Arry is a 2015-2016 story, onty the same.
Puma news might get bigger pharma to kick the tires on onty, or arry.
Arry drugs in phase 1-2 using her1-her2 mechanism.
Arry has a couple phase studies using same technology as puma, one with onty, that is up 18-19% too.
Not sure but puma ( pbyi up 287% ) on her1, her2 inhibitor drug and Arry Mek drugs might have a similar mechanism aimed at shutting down cell growth mechanism. Someone with a better medical background than I have might clarify. I believe one of our mek drugs had similar results in phase 2 for at least one indication though most phase 3 studies here are a year or two from completion.
Under the terms of the agreement OPKO is eligible for payments of up to $121 million, including an up-front payment and additional payments based upon achievement of specified regulatory and commercialization milestones; and will receive double digit tiered-royalties on sales. TESARO and OPKO will share future profits from the commercialization of licensed products in Japan and OPKO will have an option to market the products in Latin America.
Last q when they reported their losses stock ended up for the week about .30, go figure, lol. Seems if you look at the past 12 quarters you will notice the stock trades up a quarter, down a quarter or no change. Might be no one is expecting a positive earnings number for a few more quarters, so losing a .10-.30 is inconsequential. The average range on earnings is roughly up/down .25 with an average more eod roughly .12/ plus or minus, but good luck with your short.
Not really, Opko hit 8 new all time highs in 15 sessions, it ran from 8.88 to 12.95, shorts piled on all the way until it broke through 10.00, and then they spiked it to 12.95. Most longs who missed buying during those 15 sessions got in around current levels or way lower than 8.88-12.95. I am sure a few like Frost added above 8.88 at that time, but my bet is the lions share of the move was that 7.5m drop in short interest. So those saying it will head to 14-18 likely had a cost basis nearer 5.50-8.50, 12.95 would have appeared as it was, an unsustainable spike, squeeze. Next time if it gets to 12.95 on news, it can run past it, but on a no news short squeeze, umm, not yet. Give it about 4 more months and we will see.